AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)
AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)

Balance Sheet ACRX Quote AcelRx Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 80 53 88
ShortTermInvest 0 8 18
Cash 80 60 106
AccountReceivab 6 2 0
Inventories 2 1 1
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 89 63 108
PPE 17 19 20
AccumulatedDepr -7 -8 -9
NetPPE 11 11 11
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 1 1
TotalNonCurrent 11 12 13
TotalAssets 100 76 121
ShortTermDebt 3 8 9
AccountsPayable 2 1 2
TaxesPayable 0 0 0
AccruedLiabilit 2 1 1
DeferredRevenue 0 0 0
OtherCurrentLia 3 3 4
TotalCurrentLia 10 14 16
Debt 19 11 3
DeferredTaxesLi 0 0 0
DeferredRevenue 4 3 3
OtherLTLiabilit 73 84 94
TotalNonCurrent 95 98 100
TotalLiabilitie 105 112 116
CommonStock 0 0 0
AdditionalPaidI 241 261 349
RetainedEarning -246 -298 -345
AccumulatedOthe 0 0 0
TotalStockholde -5 -37 4
TotalLiabilitie 100 76 121
AcelRx Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AcelRx Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.